Skip to main
CYRX

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort is a trusted and leading provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a strong focus on supporting the rapidly growing cell and gene therapy market. The company has a proven track record of strong revenue growth, with both of its segments – Life Sciences Services and Life Sciences Products – experiencing double-digit growth in the latest quarter. Additionally, CryoPort has a strong pipeline of potential future approvals for its key customers. While there are some risks in the market and potential for competition, CryoPort's strong financial performance and expanding market share make it an attractive investment option for those looking to capitalize on the growth of the cell and gene therapy industry.

Bears say

CryoPort is experiencing strong revenue growth and is expected to see further growth in the future, but risk factors such as potential supply chain disruptions, regulatory challenges, and competition in a highly competitive and heavily regulated industry could negatively impact their financial performance. Additionally, their reliance on third parties for key software and shipping services exposes them to potential delays or failures in product delivery. These risks, combined with a current valuation at a premium compared to their small/mid-cap peers, lead to a negative outlook on CYRX stock.

CryoPort (CYRX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, CryoPort (CYRX) has a Strong Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.